42 completed. 42 Phase 2, 10 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Completed 42 |
| Phase 3 | 10 | Completed 10 |
| Phase 1 | 6 | Completed 6 |
Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia SHR-1918; SHR-1918 Placebo - Hyperlipidemia | Phase 2 | Completed | Beijing Suncadia Pharmaceuticals Co., Ltd | 44 | 2024-07-02 | 2026-02-05 |
| The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia SHR-1209, Placebo - Hyperlipidemia | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 110 | 2019-06-20 | 2022-11-30 |
| Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease VK2809, Placebo - Hyperlipidemia, NAFLD | Phase 2 | Completed | Viking Therapeutics, Inc. | 59 | 2016-09-28 | 2021-04-26 |
| The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production Insulin, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 9 | 2016-04-14 | 2017-05-08 |
| A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg ETC-1002, Atorvastatin, Placebo - Hyperlipidemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 68 | 2015-12-01 | 2019-03-29 |
| The SCCS Polypill Pilot Trial Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide) - Hypertension, Hyperlipidemia | Phase 2 | Completed | Vanderbilt University | 303 | 2015-12-01 | 2021-05-14 |
| Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans Sitagliptin, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 21 | 2012-07-01 | 2017-01-23 |
| A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes ETC-1002, Placebo - Hyperlipidemia, Type 2 Diabetes | Phase 2 | Completed | Esperion Therapeutics, Inc. | 60 | 2012-04-01 | 2019-03-29 |
| Combined Effects of Bioactive Compounds in Lipid Profile Armolipid Plus, placebo - Hyperlipidemia, Low-density-lipoprotein-type | Phase 2 / Phase 3 | Completed | Rottapharm Spain | 118 | 2012-01-01 | 2013-02-28 |
| Efficacy and Safety of Kochujang Pills on Blood Lipids Profiles in Hyperlipidemia Subjects Kochujang Pills, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Completed | Chonbuk National University Hospital | 30 | 2011-11-01 | 2013-05-30 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 160 | 2011-07-28 | 2022-11-07 |
| Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 411 | 2011-07-06 | 2022-11-08 |
| LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy Evolocumab, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 631 | 2011-07-01 | 2022-11-15 |
| Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia XueZhiKang (XZK), a botanic product with multiple components, Placebo - Hyperlipidemia | Phase 2 | Completed | Beijing Peking University WBL Biotech Co., Ltd. | 116 | 2011-04-01 | 2014-07-23 |
| Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM) PPD10558, Atorvastatin, Placebo - Myalgia, Hypercholesterolemia | Phase 2 | Completed | Furiex Pharmaceuticals, Inc | 282 | 2011-03-01 | 2011-12-22 |
| Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress Pterostilbene 50 mg twice daily, Placebo, Grape Extract - Hyperlipidemia, Blood Pressure | Phase 2 / Phase 3 | Completed | University of Mississippi Medical Center | 80 | 2010-12-01 | 2018-01-10 |
| A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia Aged garlic powder, Placebo powder - Hyperlipidemia | Phase 2 / Phase 3 | Completed | Chonbuk National University Hospital | 60 | 2010-07-01 | 2012-10-12 |
| Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation safoof e muhazzil, compressed tablet of safoof e muhazzil, Atorvastatin - Hyperlipidemia | Phase 2 | Completed | Jamia Hamdard University | 128 | 2010-05-01 | 2014-10-21 |
| Lepticore in Metabolic Syndrome and Weight Loss Lepticore - Obesity, Hyperlipidemia | Phase 1 / Phase 2 | Completed | University of Yaounde 1 | 92 | 2009-08-01 | 2010-01-12 |
| Red Yeast Rice and Phytosterols In Statin Intolerance red yeast rice, phytosterol, therapeutic lifestyle program - Hyperlipidemia | Phase 2 / Phase 3 | Completed | Chestnut Hill Health System | 200 | 2009-07-01 | 2011-07-18 |
Showing 20 of 42. Sign in to see all of them.
Hyperlipidemias (42) · Cardiovascular Diseases (8) · Hypercholesterolemia (6) · Hypertension (5) · Metabolic Syndrome (5) · Obesity (4) · Diabetes Mellitus (3) · HIV Infections (3) · Heart Diseases (3) · Hypercholesterolemia, Autosomal Dominant, 3 (3) · Insulin Resistance (3) · Patient Compliance (3) · Dyslipidemias (2) · Alzheimer Disease (1) · Coronary Disease (1)
Nutritional and Metabolic Diseases (42) · Lipid Metabolism Disorders (41) · Metabolic Diseases (41) · Dyslipidemias (40) · Glucose Metabolism Disorders (10) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (7) · Hyperinsulinism (6) · Body Weight (5) · Nutrition Disorders (5) · Overnutrition (5) · Vascular Diseases (5) · Behavior (4) · Cardiovascular Diseases (4) · Endocrine System Diseases (4)
Atorvastatin (7) · Ezetimibe (4) · Exercise (3) · evolocumab (3) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (2) · Rosuvastatin Calcium (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane (1) · 6-(4'-trifluoromethyl-6-methoxybiphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester (1) · Amlodipine (1) · BMS201038 (1) · Diet (1) · Fatty Acids, Omega-3 (1) · Fenofibrate (1) · Fish Oils (1)
University of Toronto (5) · Amgen (3) · Chonbuk National University Hospital (2) · Esperion Therapeutics, Inc. (2) · University Health Network, Toronto (2) · Aegerion Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Beijing Peking University WBL Biotech Co., Ltd. (1) · Beijing Suncadia Pharmaceuticals Co., Ltd (1) · Chestnut Hill Health System (1) · Cortria Corporation (1) · Duke University (1) · Furiex Pharmaceuticals, Inc (1) · Gilead Sciences (1) · Jamia Hamdard University (1)
United States (21) · Canada (10) · Denmark (4) · China (3) · Australia (2) · Belgium (2) · Germany (2) · Hungary (2) · Iran (2) · South Korea (2) · Spain (2) · Brazil (1) · Bulgaria (1) · Cameroon (1) · Czechia (1)
David JA Jenkins, MD, PhD, DSc (2) · Abbas Delazar, PhD (1) · Akram Pourshams, PhD (1) · Ali Eskandari, MD (1) · Angel Brea, MD (1) · Asim Ali Khan, MD (1) · Brian Roberts, M.D. (1) · Cyril WC Kendall, PhD (1) · Dal-Sik Kim, MD (1) · Daniel M Riche, Pharm.D. (1) · David Capuzzi (1) · David J Becker, MD (1) · David JA Jenkins, MD PhD DSc (1)
PMID 22301925, PMID 25091629, PMID 12221048, PMID 18018771, PMID 19592624, PMID 20435205, PMID 21041432, PMID 21741606, PMID 21752880, PMID 21831304, PMID 21846904, PMID 22169113, PMID 22743313, PMID 23019316, PMID 23431291, PMID 23816039, PMID 23884353, PMID 24077434, PMID 24385236, PMID 24584549, PMID 24961447, PMID 25057276, PMID 25084280, PMID 25208075, PMID 25660356, PMID 25882384, PMID 28751575, PMID 31532959, PMID 33644749, PMID 33853731, PMID 35039035, PMID 38018702, PMID 38489667, PMID 40587053, PMID 42714362
M01RR000096 (1), M01RR000334 (1), R01HL057354 (1), R21AG023805 (1)